186 related articles for article (PubMed ID: 36807510)
41. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
42. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
43. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.
Budimir N; Thomas GD; Dolina JS; Salek-Ardakani S
Cancer Immunol Res; 2022 Feb; 10(2):146-153. PubMed ID: 34937730
[TBL] [Abstract][Full Text] [Related]
44. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
45. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
[TBL] [Abstract][Full Text] [Related]
46. Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade.
Xu L; Li B; Pi C; Zhu Z; Tao F; Xie K; Feng Y; Xu X; Yin Y; Gu H; Fang J
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460336
[TBL] [Abstract][Full Text] [Related]
47. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
48. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
49. PES1 reduces CD8
Ma N; Hua R; Yang Y; Liu ZC; Pan J; Yu BY; Sun YF; Xie D; Wang Y; Li ZG
J Biomed Sci; 2023 Mar; 30(1):20. PubMed ID: 36959575
[TBL] [Abstract][Full Text] [Related]
50. Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.
Zhang Y; Cui Q; Xu M; Liu D; Yao S; Chen M
Front Immunol; 2022; 13():901772. PubMed ID: 35833132
[TBL] [Abstract][Full Text] [Related]
51. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
52. Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.
Natoli M; Bonito N; Robinson JD; Ghaem-Maghami S; Mao Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1391-1401. PubMed ID: 32200422
[TBL] [Abstract][Full Text] [Related]
53. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
Wen X; Shi C; Zeng X; Zhao L; Yao L; Liu Z; Feng L; Zhang D; Huang J; Li Y; Lin Q; Chen H; Zhuang R; Chen X; Zhang X; Guo Z
Clin Cancer Res; 2022 Jul; 28(13):2923-2937. PubMed ID: 35320358
[TBL] [Abstract][Full Text] [Related]
54. A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities.
Lv L; Wang H; Shi W; Wang Y; Zhu W; Liu Z; Chen X; Zheng C; Kong W; Li W; Zhu J; Lu H
Appl Microbiol Biotechnol; 2022 Nov; 106(21):7039-7050. PubMed ID: 36184689
[TBL] [Abstract][Full Text] [Related]
55. NK Cells Respond to Checkpoint Blockade.
Cancer Discov; 2018 Dec; 8(12):1498. PubMed ID: 30352860
[TBL] [Abstract][Full Text] [Related]
56. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
57. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
58. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework.
Ge YX; Zhang TW; Zhou L; Ding W; Liang HF; Hu ZC; Chen Q; Dong J; Xue FF; Yin XF; Jiang LB
Biomaterials; 2022 Mar; 282():121407. PubMed ID: 35217343
[TBL] [Abstract][Full Text] [Related]
59. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
[TBL] [Abstract][Full Text] [Related]
60. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
Stein A; Simnica D; Schultheiß C; Scholz R; Tintelnot J; Gökkurt E; von Wenserski L; Willscher E; Paschold L; Sauer M; Lorenzen S; Riera-Knorrenschild J; Depenbusch R; Ettrich TJ; Dörfel S; Al-Batran SE; Karthaus M; Pelzer U; Waberer L; Hinke A; Bauer M; Massa C; Seliger B; Wickenhauser C; Bokemeyer C; Hegewisch-Becker S; Binder M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34315821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
